Nadolol (CuraSen)

纳多洛尔 (CuraSen)

Report date: 2025/12/10 11:09:00

Base Information

Drug NameNadolol (CuraSen)
Drug Alias NameCST-107
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta adrenergic receptors antagonists
TargetsBeta adrenergic receptors
Therapy Area/IndicationsCognitive DysfunctionCognition DisordersREM Sleep Behavior Disorder +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCuraSen Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCuraSen Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCognitive DysfunctionCognition DisordersREM Sleep Behavior Disorder +[5] 
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A